Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031837 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Gary Morrow.
- Terminated
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00031837 is a Phase 3 study that was terminated before completion, run by Gary Morrow. The registered enrollment target is 400 participants.
The verdict
NCT00031837, a Phase 3 study, was terminated before completion, sponsored by Gary Morrow.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG gemcitabine hydrochloride
- DRUG dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031837
The ClinicalTrials.gov registry entry for NCT00031837 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00031837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031837 about?
NCT00031837 is a clinical study titled "Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Anticoagulants such as dalteparin may help prevent blood clots in patients being treated with gemcitabine for unresectable or metastatic pancreatic cancer...
What is the current status of trial NCT00031837?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2002-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00031837?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), gemcitabine hydrochloride (DRUG), dalteparin (DRUG).
Who is sponsoring clinical trial NCT00031837?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.